KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Operating Income (2018 - 2025)

Historic Operating Income for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$10.0 million.

  • Esperion Therapeutics' Operating Income rose 3785.72% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 27854.76%. This contributed to the annual value of $54.4 million for FY2024, which is 13497.1% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Operating Income of -$10.0 million as of Q3 2025, which was up 3785.72% from $7.1 million recorded in Q2 2025.
  • Esperion Therapeutics' Operating Income's 5-year high stood at $72.3 million during Q1 2024, with a 5-year trough of -$82.8 million in Q1 2021.
  • For the 5-year period, Esperion Therapeutics' Operating Income averaged around -$28.0 million, with its median value being -$37.1 million (2023).
  • In the last 5 years, Esperion Therapeutics' Operating Income surged by 24868.63% in 2024 and then crashed by 13057.47% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Operating Income (Quarter) stood at -$55.6 million in 2021, then rose by 23.58% to -$42.5 million in 2022, then increased by 0.34% to -$42.4 million in 2023, then skyrocketed by 89.57% to -$4.4 million in 2024, then plummeted by 125.32% to -$10.0 million in 2025.
  • Its Operating Income stands at -$10.0 million for Q3 2025, versus $7.1 million for Q2 2025 and -$22.1 million for Q1 2025.